Articles producció científica> Ciències Mèdiques Bàsiques

In Vitro Antifungal Activity of Ibrexafungerp (SCY-078) Against Contemporary Blood Isolates From Medically Relevant Species of Candida: A European Study

  • Datos identificativos

    Identificador: imarina:9267642
    Handle: https://hdl.handle.net/20.500.11797/imarina9267642
    Autores:
    Quindós GMiranda-Cadena KSan-Millán RBorroto-Esoda KCantón ELinares-Sicilia MJHamprecht AMontesinos ITortorano AMPrigitano AVidal-García MMarcos-Arias CGuridi ASanchez-Reus FMachuca-Bárcena JRodríguez-Iglesias MAMartín-Mazuelos ECastro-Méndez CLópez-Soria LRuiz-Gaitán AFernandez-Rivero MLorenzo DCapilla JRezusta APemán JGuarro JPereira JPais CRomeo OEzpeleta GJauregizar NAngulo DEraso E
    Resumen:
    Background: Ibrexafungerp (SCY-078) is the newest oral and intravenous antifungal drug with broad activity, currently undergoing clinical trials for invasive candidiasis. Objective: The aim of this study was to assess the in vitro activity of ibrexafungerp and comparators against a collection of 434 European blood isolates of Candida. Methods: Ibrexafungerp, caspofungin, fluconazole, and micafungin minimum inhibitory concentrations (MICs) were collected from 12 European laboratories for 434 blood isolates, including 163 Candida albicans, 108 Candida parapsilosis, 60 Candida glabrata, 40 Candida tropicalis, 29 Candida krusei, 20 Candida orthopsilosis, 6 Candida guilliermondii, 2 Candida famata, 2 Candida lusitaniae, and 1 isolate each of Candida bracarensis, Candida catenulata, Candida dubliniensis, and Candida kefyr. MICs were determined by the EUCAST broth microdilution method, and isolates were classified according to recommended clinical breakpoints and epidemiological cutoffs. Additionally, 22 Candida auris from different clinical specimens were evaluated. Results: Ibrexafungerp MICs ranged from 0.016 to ≥8 mg/L. The lowest ibrexafungerp MICs were observed for C. albicans (geometric MIC 0.062 mg/L, MIC range 0.016–0.5 mg/L) and the highest ibrexafungerp MICs were observed for C. tropicalis (geometric MIC 0.517 mg/L, MIC range 0.06–≥8 mg/L). Modal MICs/MIC50s (mg/L) against Candida spp. were 0.125/0.06 for C. albicans, 0.5/0.5 for C. parapsilosis, 0.25/0.25 for C. glabrata, 0.5/0.5 for C. tropicalis, 1/1 for C. krusei, 4/2 for C. orthopsilosis, and 0.5/0.5 for C. auris. Ibrexafungerp showed activity against fluconazole- and echinocandin-resistant isolates. If adopting wild-type upper limits, a non-wild-type phenotype for ibrexafungerp was only observed for 16/434 (3.

  • Otros:

    Autor según el artículo: Quindós G; Miranda-Cadena K; San-Millán R; Borroto-Esoda K; Cantón E; Linares-Sicilia MJ; Hamprecht A; Montesinos I; Tortorano AM; Prigitano A; Vidal-García M; Marcos-Arias C; Guridi A; Sanchez-Reus F; Machuca-Bárcena J; Rodríguez-Iglesias MA; Martín-Mazuelos E; Castro-Méndez C; López-Soria L; Ruiz-Gaitán A; Fernandez-Rivero M; Lorenzo D; Capilla J; Rezusta A; Pemán J; Guarro J; Pereira J; Pais C; Romeo O; Ezpeleta G; Jauregizar N; Angulo D; Eraso E
    Departamento: Ciències Mèdiques Bàsiques
    Autor/es de la URV: Capilla Luque, Javier / Guarro Artigas, Josep / LORENZO GUTIÉRREZ, DÀMARIS
    Palabras clave: Scy-078 Micafungin Ibrexafungerp Eucast Caspofungin Candida Antifungal testing Antifungal resistance
    Resumen: Background: Ibrexafungerp (SCY-078) is the newest oral and intravenous antifungal drug with broad activity, currently undergoing clinical trials for invasive candidiasis. Objective: The aim of this study was to assess the in vitro activity of ibrexafungerp and comparators against a collection of 434 European blood isolates of Candida. Methods: Ibrexafungerp, caspofungin, fluconazole, and micafungin minimum inhibitory concentrations (MICs) were collected from 12 European laboratories for 434 blood isolates, including 163 Candida albicans, 108 Candida parapsilosis, 60 Candida glabrata, 40 Candida tropicalis, 29 Candida krusei, 20 Candida orthopsilosis, 6 Candida guilliermondii, 2 Candida famata, 2 Candida lusitaniae, and 1 isolate each of Candida bracarensis, Candida catenulata, Candida dubliniensis, and Candida kefyr. MICs were determined by the EUCAST broth microdilution method, and isolates were classified according to recommended clinical breakpoints and epidemiological cutoffs. Additionally, 22 Candida auris from different clinical specimens were evaluated. Results: Ibrexafungerp MICs ranged from 0.016 to ≥8 mg/L. The lowest ibrexafungerp MICs were observed for C. albicans (geometric MIC 0.062 mg/L, MIC range 0.016–0.5 mg/L) and the highest ibrexafungerp MICs were observed for C. tropicalis (geometric MIC 0.517 mg/L, MIC range 0.06–≥8 mg/L). Modal MICs/MIC50s (mg/L) against Candida spp. were 0.125/0.06 for C. albicans, 0.5/0.5 for C. parapsilosis, 0.25/0.25 for C. glabrata, 0.5/0.5 for C. tropicalis, 1/1 for C. krusei, 4/2 for C. orthopsilosis, and 0.5/0.5 for C. auris. Ibrexafungerp showed activity against fluconazole- and echinocandin-resistant isolates. If adopting wild-type upper limits, a non-wild-type phenotype for ibrexafungerp was only observed for 16/434 (3.7%) isolates: 11 (4.6%) C. parapsilosis, 4 (5%) C. glabrata, and 1 (2.5%) C. tropicalis. Conclusion: Ibrexafungerp showed a potent in vitro activity against Candida.
    Áreas temáticas: Saúde coletiva Química Odontología Microbiology (medical) Microbiology Medicine (miscellaneous) Medicina veterinaria Medicina iii Medicina ii Medicina i Interdisciplinar Infectious diseases Immunology Geociências Farmacia Ensino Ciências biológicas iii Ciências biológicas ii Ciências biológicas i Ciências agrárias i Biotecnología Biodiversidade
    Acceso a la licencia de uso: https://creativecommons.org/licenses/by/3.0/es/
    Direcció de correo del autor: josep.guarro@urv.cat javier.capilla@urv.cat
    Identificador del autor: 0000-0002-7839-7568 0000-0002-0765-6403
    Fecha de alta del registro: 2024-08-24
    Versión del articulo depositado: info:eu-repo/semantics/publishedVersion
    URL Documento de licencia: https://repositori.urv.cat/ca/proteccio-de-dades/
    Referencia al articulo segun fuente origial: Frontiers In Cellular And Infection Microbiology. 12
    Referencia de l'ítem segons les normes APA: Quindós G; Miranda-Cadena K; San-Millán R; Borroto-Esoda K; Cantón E; Linares-Sicilia MJ; Hamprecht A; Montesinos I; Tortorano AM; Prigitano A; Vidal- (2022). In Vitro Antifungal Activity of Ibrexafungerp (SCY-078) Against Contemporary Blood Isolates From Medically Relevant Species of Candida: A European Study. Frontiers In Cellular And Infection Microbiology, 12(), -. DOI: 10.3389/fcimb.2022.906563
    Entidad: Universitat Rovira i Virgili
    Año de publicación de la revista: 2022
    Tipo de publicación: Journal Publications

  • Palabras clave:

    Immunology,Infectious Diseases,Medicine (Miscellaneous),Microbiology,Microbiology (Medical)
    Scy-078
    Micafungin
    Ibrexafungerp
    Eucast
    Caspofungin
    Candida
    Antifungal testing
    Antifungal resistance
    Saúde coletiva
    Química
    Odontología
    Microbiology (medical)
    Microbiology
    Medicine (miscellaneous)
    Medicina veterinaria
    Medicina iii
    Medicina ii
    Medicina i
    Interdisciplinar
    Infectious diseases
    Immunology
    Geociências
    Farmacia
    Ensino
    Ciências biológicas iii
    Ciências biológicas ii
    Ciências biológicas i
    Ciências agrárias i
    Biotecnología
    Biodiversidade

  • Documentos:

    DocumentPrincipal

  • Cerca a google

    Search to google scholar